Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Louis Schuster
Effect of Disease-Modifying Anti-Rheumatic Drugs on Bone Structure and Strength in Psoriatic Arthritis Patients
Arthritis Research & Therapy
Cortical Bone Loss Is an Early Feature of Nonradiographic Axial Spondyloarthritis
Arthritis Research & Therapy
Related publications
Safety, Cost and Effectiveness Issues With Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Can Disease-Modifying Anti-Rheumatic Drugs Reduce the Risk of Developing Dementia in Patients With Rheumatoid Arthritis?
Neurotherapeutics
Neurology
Pharmacology
OP0281-HPR Preferences of Patients With Rheumatoid Arthritis Regarding Disease Modifying Anti-Rheumatic Drugs: A Discrete Choice Experiment
Patient Preferences in the Choice of Disease Modifying Anti-Rheumatic Drugs
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
PHS30 Health Care Costs in Psoriatic Arthritis (PSA) Patients Newly Initiated on a Biologic Disease-Modifying Anti-Rheumatic Drug (DMARDS) or Methotrexate (MTX)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
AB0490 Evaluation of Inhibitory Factor of Radiographic Progression by Iguratimod Add-On Therapy in Rheumatoid Arthritis Patients With Inadequate Responses to Disease-Modifying Anti-Rheumatic Drugs
Biological Disease-Modifying Antirheumatic Drugs in Juvenile Idiopathic Arthritis of Polyarticular Course, Enthesitis-Related Arthritis, and Psoriatic Arthritis: A Consensus Statement
Biological Targets in the Treatment of Rheumatoid Arthritis: A Comprehensive Review of Current and In-Development Biological Disease Modifying Anti-Rheumatic Drugs
Biologics: Targets and Therapy
Oncology
Immunology
Gastroenterology
Pharmacology
Rheumatology
Allergy
Factors Associated With Quality of Life and Functional Disability Among Rheumatoid Arthritis Patients Treated With Disease-Modifying Anti-Rheumatic Drugs for at Least Six-Months
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
